Sperm-associated antigen 9 is a promising marker for early diagnosis of endometrial cancer.
BACKGROUND
Sperm-associated antigen 9 (SPAG9) has been recently proposed as a novel biomarker for early diagnosis of several human tumors, including ovarian, cervical and breast cancers. Its clinical value remains to be clarified for endometrial cancer (EC). In this study, we investigated the utility of serum SPAG9 levels in diagnosis of EC and its association with important clinicopathological parameters.


METHODS
This cross-sectional study was performed at a tertiary women's referral center in Ankara, Turkey. Preoperative serum samples were collected from patients surgically treated for endometrial cancer between June 2012-April 2013. Similar aged women with a biopsy proven benign endometrium were used as controls. Serum SPAG9 levels were measured with an enzyme-linked immunosorbent assay (ELISA) method and assessed for links with clinicopathological factors. Receiver operating characteristic (ROC) curve analysis was performed to assess power of SPAG9 levels for EC prediction. P values less than 0.05 were considered statistically significant.


RESULTS
A total of 63 women with EC and 27 with benign endometrium were included in the study. Mean age in the EC group was 58.7±1.1. Median SPAG9 levels in the EC and control groups were 18.3 (range, 12.7-53.8) and 14.1 (range, 4.3-65.3), respectively (p<0.001). A cut-off value of 17 ng/ml for SPAG9 predicted presence of malignant endometrium with 74% sensitivity and 83% specificity [Area under curve (AUC)=0.82, p<0.001]. SPAG9 levels did not demonstrate any significant association with histological type, FIGO stage, tumor grade, size, myometrial invasion, lymphovascular space invasion, cervical involvement, adnexal involvement, peritoneal cytology or lymph node status (all p>0.05).


CONCLUSIONS
Testing for SPAG9 may be useful for early detection of EC in asymptomatic high-risk women. Its role in post-treatment follow-up and early detection of recurrence should be assessed in future trials.
Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Education and Research Hospital, Ankara, Turkey E-mail : eralpbaser@gmail.com.
Eralp
E
Baser
Cihan
C
Togrul
Emre
E
Ozgu
Sevgi
S
Ayhan
Mete
M
Caglar
Salim
S
Erkaya
Tayfun
T
Gungor
D048868:Adaptor Proteins, Signal Transducing / Q000097:blood*; D018262:Adenocarcinoma, Clear Cell / Q000097:blood / Q000175:diagnosis*; D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000097:blood*; D002291:Carcinoma, Papillary / Q000097:blood / Q000175:diagnosis*; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D018284:Cystadenocarcinoma, Serous / Q000097:blood / Q000175:diagnosis*; D042241:Early Diagnosis; D016889:Endometrial Neoplasms / Q000097:blood / Q000175:diagnosis*; D004717:Endometrium / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D012372:ROC Curve
D048868:Adaptor Proteins, Signal Transducing; D014408:Biomarkers, Tumor; C111047:SPAG9 protein, human